Category Archives: Global News Feed

Translate Bio to Participate in Upcoming Investor Conferences

By Global News Feed

LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences:

Read the original here:
Translate Bio to Participate in Upcoming Investor Conferences

OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

By Global News Feed

SUWON, Republic of Korea, Sept. 29, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, presents two virtual posters of their on-going clinical research at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society on September 27 – 30. The presentations will focus on the results of the Company’s proprietary asymmetric siRNA (asiRNA) study, which confirms the therapeutic effects of RNAi-based therapeutics in patients with hepatic diseases and age-related macular degeneration.

Read the original post:
OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

AnPac Bio Announces Equity Investment from Keystone Capital Partners for up to $7 Million

By Global News Feed

SAN JOSE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today that the Company has entered into an agreement with Keystone Capital Partners (“Keystone”) for a preferred stock investment of US$7.0 Million. Additional details on the transaction are outlined in the accompanying Registration Statement filed on September 30, 2020 (File No. 333?249170).

Read the original here:
AnPac Bio Announces Equity Investment from Keystone Capital Partners for up to $7 Million

Evaxion Biotech Launches New AI Powered Platform, RAVEN, to Enable Faster Response to Emerging Viral Pandemics

By Global News Feed

COPENHAGEN, Denmark, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies and vaccines, announces today that it has received DKK 4.8 million (approx. $800,000) in funding from Innovation Fund Denmark for the development of its new RAVEN platform, an integral part of Evaxion’s Adaptive and Intelligent Vaccine for a Rapid Response against Corona Viruses (AICoV) program.

Continued here:
Evaxion Biotech Launches New AI Powered Platform, RAVEN, to Enable Faster Response to Emerging Viral Pandemics

Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock

By Global News Feed

WESTLAKE VILLAGE, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the commencement of an underwritten public offering of 4,000,000 shares of its common stock. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to 600,000 additional shares of its common stock.

Read more:
Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock

Major shareholder announcement

By Global News Feed

Orphazyme A/SCompany announcement                                                                                       No. 60/2020                                                                                                           Company Registration No. 32266355

See the original post here:
Major shareholder announcement

Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference

By Global News Feed

WOBURN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team will present in a fireside chat and host investor meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference being held on October 6, 2020 at 4:45 p.m. ET.

Go here to read the rest:
Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference

SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock

By Global News Feed

STAMFORD, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Originally posted here:
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock